
Robin Carhart-Harris, PhD
Prof. Carhart-Harris became the Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco (UCSF) in 2021 and founded the Carhart-Harris Lab at UCSF in 2023. He moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. Prof. Carhart-Harris and colleagues have conducted multimodal human functional neuroimaging studies with LSD, psilocybin, MDMA, and DMT, as well as clinical trials of psilocybin therapy for various disorders, including three trials in depression, and additional trials in anorexia and fibromyalgia syndrome. He has published in The New England Journal of Medicine, Nature, Nature Medicine, Cell, Lancet Psychiatry, Science Advances, JAMA Psychiatry, American Journal of Psychiatry, Proceedings of the National Academy of Sciences, and more. In April 2019, he founded the Centre for Psychedelic Research at Imperial College London, the first of its kind in the world. He spoke at the World Economic Forum (WEF) in Davos in 2019, was named among the top 31 medical scientists by The Times newspaper in 2020, was listed in TIME magazine’s “100 Next” in 2021, was voted Psychedelic Researcher of the Year in 2021, and was included in Vox magazine’s “Future 50” in 2023—a list of positive change-makers. His current research program at UCSF focuses on the mechanisms of action of psychedelics and psychedelic therapy.